292
Participants
Start Date
December 19, 2017
Primary Completion Date
January 13, 2021
Study Completion Date
January 10, 2025
nivolumab
Specified dose on specified days
docetaxel
Specified dose on specified days
enzalutamide
Specified dose on specified days
rucaparib
Specified dose on specified days
prednisone
Specified dose on specified days
Local Institution - 0050, Clayton
Local Institution - 0027, Montería
Local Institution - 0026, Medellín
Local Institution - 0043, CABA
Local Institution - 0052, CABA
Local Institution - 0042, Capital Federal
Local Institution - 0015, Camperdown
Local Institution - 0017, Westmead
Local Institution - 0013, Heidelberg
Local Institution - 0014, South Brisbane
Local Institution - 0062, Villa Siburu
Local Institution - 0016, Elizabeth Vale
Local Institution - 0068, New York
Local Institution - 0038, Albany
Local Institution - 0030, Marseille
Local Institution - 0053, Allentown
Local Institution - 0040, Rockville
Local Institution - 0039, Fairfax
Local Institution - 0033, Besançon
Local Institution - 0041, Durham
Local Institution - 0045, Madrid
Local Institution - 0009, Marietta
Local Institution - 0046, Pamplona
Local Institution - 0037, Miami
Local Institution - 0036, Daphne
Local Institution - 0054, León
Local Institution - 0006, Göttingen
Local Institution - 0069, Jackson
Local Institution - 0065, Louisville
Local Institution - 0047, Seville
Local Institution - 0061, Guadalajara
Local Institution - 0048, Guadalajara
Local Institution - 0001, Essen
Local Institution - 0012, Detroit
Local Institution - 0007, Koblenz
Local Institution - 0032, Clermont-Ferrand
Local Institution - 0011, St Louis
Local Institution - 0035, Omaha
Local Institution - 0031, Lyon
Tulane University, New Orleans
Local Institution - 0025, Culiacán
Local Institution - 0064, München
Local Institution - 0010, Rancho Mirage
Local Institution - 0029, Villejuif
Local Institution - 0024, Portland
Local Institution - 0051, Viña del Mar
Local Institution - 0034, Santiago
Local Institution - 0021, Porto Alegre
Local Institution - 0049, New Haven
Boston Medical Center, Boston
Local Institution - 0044, Buenos Aires
Local Institution - 0020, Belo Horizonte
Local Institution - 0074, Belo Horizonte
Local Institution - 0075, Curitiba
Local Institution - 0018, Ijuí
Local Institution - 0022, Campinas
Local Institution - 0071, São Paulo
Local Institution - 0019, Rio de Janeiro
Local Institution - 0073, São Paulo
Local Institution - 0067, Kelowna
Local Institution - 0059, Moncton
Local Institution - 0055, Hamilton
Local Institution - 0066, Montreal
Local Institution - 0056, Québec
Local Institution - 0004, Heidelberg
Local Institution - 0002, Jena
Lead Sponsor
Collaborators (2)
Clovis Oncology, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Bristol-Myers Squibb
INDUSTRY